Naoko Takebe

422 total citations
17 papers, 102 citations indexed

About

Naoko Takebe is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Naoko Takebe has authored 17 papers receiving a total of 102 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Oncology. Recurrent topics in Naoko Takebe's work include Lung Cancer Treatments and Mutations (5 papers), Sarcoma Diagnosis and Treatment (4 papers) and DNA Repair Mechanisms (2 papers). Naoko Takebe is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Sarcoma Diagnosis and Treatment (4 papers) and DNA Repair Mechanisms (2 papers). Naoko Takebe collaborates with scholars based in United States, Philippines and Canada. Naoko Takebe's co-authors include Nagla Abdel Karim, Abdul Rafeh Naqash, Nobuyuki Takahashi, Triparna Sen, Amin H. Nassar, Sonam Puri, Sherry X. Yang, Sally Hunsberger, Margaret Mooney and Lauren Saguilig and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nature Reviews Clinical Oncology.

In The Last Decade

Naoko Takebe

15 papers receiving 101 citations

Peers

Naoko Takebe

ONCOL

EPIDE

PRM

NEURO

Sarah Curry Ireland

Marina Sahade Brazil

Rachel Roberts‐Thomson Australia

Claire Briandet France

Lotus Yung United States

Bernhard Volz Germany

Simon Kreutzfeldt Germany

Friederike Christen Germany

Yun Jee Kang United States

Mohamed Elfagieh Libya

Sarah Curry Ireland

Naoko Takebe

32 ×0.6

ONCOL

55 ×1.4

14 ×0.7

EPIDE

17 ×0.8

PRM

5 ×0.3

NEURO

Citations per year, relative to Naoko Takebe Naoko Takebe (= 1×) peers Sarah Curry

Countries citing papers authored by Naoko Takebe

Since Specialization

Citations

This map shows the geographic impact of Naoko Takebe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoko Takebe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoko Takebe more than expected).

Fields of papers citing papers by Naoko Takebe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naoko Takebe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoko Takebe. The network helps show where Naoko Takebe may publish in the future.

Co-authorship network of co-authors of Naoko Takebe

This figure shows the co-authorship network connecting the top 25 collaborators of Naoko Takebe. A scholar is included among the top collaborators of Naoko Takebe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naoko Takebe. Naoko Takebe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Patel, Sandip Pravin, Young Kwang Chae, Shiruyeh Schokrpur, et al.. (2025). Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma. npj Precision Oncology. 9(1). 24–24. 1 indexed citations

Scott, Susan C., Anna F. Farago, W. Victoria Lai, et al.. (2025). A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 95(1). 37–37.

Sen, Triparna, Nobuyuki Takahashi, Naoko Takebe, et al.. (2024). Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. Nature Reviews Clinical Oncology. 21(8). 610–627. 43 indexed citations

Salkeni, Mohamad A., et al.. (2024). Advanced Granulosa Cell Tumors of the Ovary: A Review with a Focus on Current and Novel Therapeutic Approaches. SHILAP Revista de lepidopterología. 7(4). 263–271. 1 indexed citations

Karlovich, Chris, Jennifer L. Silhavy, Biswajit Das, et al.. (2023). Blood-based assessment of patients with mismatch repair-deficient tumors enrolled in NCI-MATCH Arm Z1D (nivolumab).. Journal of Clinical Oncology. 41(16_suppl). 2560–2560.

Eroglu, Zeynep, Janice M. Mehnert, Anita Giobbie‐Hurder, et al.. (2023). Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).. Journal of Clinical Oncology. 41(16_suppl). 9511–9511. 3 indexed citations

Lee, Alice A., Alexander J. Chou, P. Mickey Williams, et al.. (2023). Erdafitinb in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B).. Journal of Clinical Oncology. 41(16_suppl). 10007–10007. 11 indexed citations

Macy, Margaret E., Rajen Mody, Joel M. Reid, et al.. (2023). Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4/6-INK4a-Rb pathway: Results from NCI-COG pediatric MATCH trial Arm I (APEC1621I).. Journal of Clinical Oncology. 41(16_suppl). 10006–10006. 4 indexed citations

Vo, Kieuhoa T., Amit J. Sabnis, Sinchita Roy‐Chowdhuri, et al.. (2022). Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J).. Journal of Clinical Oncology. 40(16_suppl). 3009–3009. 7 indexed citations

10.

Coyne, Geraldine O’Sullivan, Shivaani Kummar, Seth M. Steinberg, et al.. (2022). Extended progression-free survival and long-term safety of nirogacestat in patients with desmoid tumors.. Journal of Clinical Oncology. 40(16_suppl). 11545–11545. 5 indexed citations

11.

Frankel, Paul, Jan H. Beumer, Naoko Takebe, et al.. (2022). A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.. Journal of Clinical Oncology. 40(16_suppl). TPS3174–TPS3174. 3 indexed citations

12.

Shin, Sarah J., Geraldine O’Sullivan Coyne, Shivaani Kummar, et al.. (2022). Safety, pharmacodynamic, and clinical response evaluation of nilotinib and paclitaxel in adults with refractory solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 3026–3026. 1 indexed citations

13.

Salkeni, Mohamad A., Anthony P. Conley, Elizabeth J. Davis, et al.. (2022). A phase 2 study of anti-PD-L1 antibody (atezolizumab) in grade 2 and 3 chondrosarcoma.. Journal of Clinical Oncology. 40(16_suppl). 11528–11528. 2 indexed citations

14.

Chi, Susan, P. Mickey Williams, Sinchita Roy‐Chowdhuri, et al.. (2022). Tazemetostat in patients with tumors with alterations in EZH2 or the SWI/SNF complex: Results from NCI-COG Pediatric MATCH trial Arm C (APEC1621C).. Journal of Clinical Oncology. 40(16_suppl). 10009–10009. 11 indexed citations

15.

Tsao, Anne S., Alan L. Ho, Janice M. Mehnert, et al.. (2022). Phase II study of vismodegib in patients with SMO or PTCH1 mutated tumors: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T.. Journal of Clinical Oncology. 40(16_suppl). 3010–3010. 1 indexed citations

16.

Meehan, Robert, Geraldine O’Sullivan Coyne, Shivaani Kummar, et al.. (2017). A phase I trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with solid tumors and lymphomas.. Journal of Clinical Oncology. 35(15_suppl). 2518–2518. 1 indexed citations

17.

Takebe, Naoko, Sally Hunsberger, & Sherry X. Yang. (2012). Expression of Gli1 in the hedgehog signaling pathway and breast cancer recurrence. Chinese Journal of Cancer Research. 24(4). 257–258. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact